Discovery of Potential Anti-Tuberculosis Agents Through Computer-Aided Drug Design: QSAR, DFT, Molecular Docking, ADMET Predictions and Molecular Dynamics Simulation

Authors:

Abstract
Tuberculosis is a tropical and a multi-drug resistant disease, causing millions of deaths and without any its pathogen, mycobacterium has developed resistance to several key antibiotics, which results in the emergence of extensively drug-resistant (XDR) and multidrug-resistant (MDR) strains. This research aimed at employing QSAR, molecular docking, MD simulation, and other analysis in order to come up with a promising compound that may help to change the current situation. Outcomes from this study showed highly hopeful results, which indicates that the chosen model developed, model 1 exhibits a predictive power that is dependable and confirmed to be a model that is most successful than the other three models, with validation metrics, including R2trn =0.927, R2adj = 0.910, Q2cv =0.874, and R2ext = 0.867. Furthermore, the p-values, mean effect values, and the Y-scrambling test also confirmed that model 1 is the most significant and robust of the model descriptors selected. The impact and reliability of the selected descriptors of the model were validated by these analyses, which strengthen its predictive abilities. Docking studies revealed that, excellent interactions within the active region of gyrB (3ZKB) were demonstrated by an analogue compound 17a when compared to both the template, other analogues and the Isoniazid drug, suggesting potential compounds 17a to be the most effective enzyme target. Complex1 (compound 17a-3ZKB) MD simulations results revealed an outstanding stability, demonstrated by several analyses. This recommended that it holds a promise as potential treatment for tuberculosis.